Tokyo, Feb. 3 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000060552) titled 'Physicians' practical status about treat to target in ulcerative colitis' on Feb. 2.
Study Type:
Observational
Primary Sponsor:
Institute - EA Pharma Co., Ltd.
Condition:
Condition - Ulcerative colitis
Classification by malignancy - Others
Genomic information - NO
Objective:
Narrative objectives1 - The objective of this study is to elucidate, through an internet based survey, the level of awareness and implementation of the treat to target (T2T) strategy in the clinical management of ulcerative colitis (UC) in Japan, and to characterize the current patterns of biomarker utilization as well as the factors underlying clinical decision making.
Basic objectives2 - Others
Eligibility:
Age-lower limit - Not applicable
Age-upper limit - Not applicable
Gender - Male and Female
Key inclusion criteria - Physicians who provide care for patients with ulcerative colitis and are registered in the research cooperation panel of Cross Marketing Co., Ltd., and who have agreed to participate in this survey
Key exclusion criteria - None
Target Size - 300
Recruitment Status:
Recruitment status - Preinitiation
Date of protocol fixation - 2026 Year 01 Month 15 Day
Anticipated trial start date - 2026 Year 02 Month 12 Day
Last follow-up date - 2026 Year 02 Month 27 Day
To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000069161
Disclaimer: Curated by HT Syndication.
